Generic Name and Formulations:
Ertapenem (as sodium) 1g; pwd for IV infusion after reconstitution and dilution; or for IM inj after reconstitution; sodium content 6mEq/g.
Merck & Co., Inc.
Indications for INVANZ:
Susceptible moderate to severe infections including complicated intraabdominal, complicated skin and skin structure, community-acquired pneumonia, complicated UTIs, acute pelvic infections. Prevention of surgical site infection following elective colorectal surgery in adults.
Adults and Children:
Do not mix or co-infuse with other meds or diluents containing dextrose. Give by IV infusion over 30 minutes for up to 14 days; or, give by IM inj for up to 7 days (for IM: see note). <3months: not recommended. 3months–12yrs: 15mg/kg twice daily (max 1g/day). ≥13yrs: 1g once daily; renal dysfunction (CrCl ≤30mL/min): 500mg once daily (give supplemental 150mg after session if dosed within 6 hours of hemodialysis). Intraabdominal: treat 5–14 days. Skin and skin structure: treat 7–14 days. Pneumonia, UTIs: treat 10–14 days (may switch to oral antibiotic after 3 days). Pelvic: treat 3–10 days. Adult prophylaxis in colorectal surgery: 1g single IV dose given 1 hour prior to surgical incision.
Penicillin, cephalosporin, or other β-lactam allergy. IM administration in patients with known hypersensitivity to amide-type local anesthetics.
CNS disorders (eg, brain lesions, seizure history). Renal dysfunction. Avoid extravasation. Monitor renal, hepatic, and hematopoetic function in prolonged use. Avoid blood vessel if administering by IM. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid: not recommended. Antagonizes valproic acid or divalproex sodium: not recommended; consider other antibacterials.
Diarrhea (evaluate if occurs), nausea, vomiting, inj site reactions (thrombophlebitis/phlebitis), headache, CNS effects (dizziness, altered mental state, rarely: seizures), edema, dyspnea, fever.
For IM use, reconstitute with lidocaine 1% only; see full labeling.
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|